AR052052A1 - Terapia de combinacion - Google Patents
Terapia de combinacionInfo
- Publication number
- AR052052A1 AR052052A1 ARP050105303A ARP050105303A AR052052A1 AR 052052 A1 AR052052 A1 AR 052052A1 AR P050105303 A ARP050105303 A AR P050105303A AR P050105303 A ARP050105303 A AR P050105303A AR 052052 A1 AR052052 A1 AR 052052A1
- Authority
- AR
- Argentina
- Prior art keywords
- combination therapy
- hydrochlorothiazide
- telmisartan
- angiotensin
- treatment
- Prior art date
Links
- 238000002648 combination therapy Methods 0.000 title 1
- RMMXLENWKUUMAY-UHFFFAOYSA-N telmisartan Chemical compound CCCC1=NC2=C(C)C=C(C=3N(C4=CC=CC=C4N=3)C)C=C2N1CC(C=C1)=CC=C1C1=CC=CC=C1C(O)=O RMMXLENWKUUMAY-UHFFFAOYSA-N 0.000 abstract 4
- JZUFKLXOESDKRF-UHFFFAOYSA-N Chlorothiazide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC2=C1NCNS2(=O)=O JZUFKLXOESDKRF-UHFFFAOYSA-N 0.000 abstract 3
- 229960002003 hydrochlorothiazide Drugs 0.000 abstract 3
- 239000005537 C09CA07 - Telmisartan Substances 0.000 abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 abstract 2
- 229960005187 telmisartan Drugs 0.000 abstract 2
- 102000008873 Angiotensin II receptor Human genes 0.000 abstract 1
- 108050000824 Angiotensin II receptor Proteins 0.000 abstract 1
- 206010020772 Hypertension Diseases 0.000 abstract 1
- 239000002333 angiotensin II receptor antagonist Substances 0.000 abstract 1
- 229940126317 angiotensin II receptor antagonist Drugs 0.000 abstract 1
- 239000005557 antagonist Substances 0.000 abstract 1
- 230000036772 blood pressure Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
- Medicinal Preparation (AREA)
Abstract
Una composicion farmacéutica que comprende aproximadamente 80mg de telmisartano y aproximadamente 25mg de hidroclorotiazida, o aproximadamente 160mg de telmisartano y aproximadamente 50 mg de hidroclorotiazida, para el tratamiento de la hipertension en pacientes con una reduccion de la tension arterial insuficiente tras un tratamiento con un antagonista del receptor de angiotensina II, o una composicion farmacéutica de un antagonista del receptor de angiotensina II y una dosis de hidroclorotiazida.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US63706204P | 2004-12-17 | 2004-12-17 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR052052A1 true AR052052A1 (es) | 2007-02-28 |
Family
ID=35589356
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP050105303A AR052052A1 (es) | 2004-12-17 | 2005-12-16 | Terapia de combinacion |
Country Status (15)
| Country | Link |
|---|---|
| EP (1) | EP1827424A1 (es) |
| JP (1) | JP2008524136A (es) |
| KR (1) | KR20070097511A (es) |
| CN (1) | CN101080225A (es) |
| AR (1) | AR052052A1 (es) |
| AU (1) | AU2005315855A1 (es) |
| BR (1) | BRPI0519656A2 (es) |
| CA (1) | CA2589493A1 (es) |
| EA (1) | EA200701159A1 (es) |
| IL (1) | IL183944A0 (es) |
| NO (1) | NO20072325L (es) |
| PE (1) | PE20060768A1 (es) |
| TW (1) | TW200637546A (es) |
| UY (1) | UY29274A1 (es) |
| WO (1) | WO2006063737A1 (es) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7232828B2 (en) | 2002-08-10 | 2007-06-19 | Bethesda Pharmaceuticals, Inc. | PPAR Ligands that do not cause fluid retention, edema or congestive heart failure |
| US8637078B2 (en) * | 2005-11-24 | 2014-01-28 | Boehringer Ingelheim International Gmbh | Bilayer tablet comprising telmisartan and diuretic |
| EP1970053A1 (en) * | 2007-03-14 | 2008-09-17 | Boehringer Ingelheim Pharma GmbH & Co. KG | Pharmaceutical composition |
| MY147827A (en) * | 2007-10-19 | 2013-01-31 | Otsuka Pharma Co Ltd | Pharmaceutical solid preparation |
| EP2203158A4 (en) | 2007-10-30 | 2012-12-26 | Reddys Lab Ltd Dr | PHARMACEUTICAL FORMULATIONS WITH TELMISARTAN AND HYDROCHLORTHIAZIDE |
| WO2009115301A1 (en) | 2008-03-19 | 2009-09-24 | Ratiopharm Gmbh | Solid pharmaceutical composition comprising a non-peptide angiotensin ii receptor antagonist and a diuretic |
| AU2009277455A1 (en) | 2008-07-31 | 2010-02-04 | Takeda Pharmaceutical Company Limited | Solid pharmaceutical composition |
| GB0822170D0 (en) * | 2008-12-04 | 2009-01-14 | Arrow Int Ltd | Telmisartan with diuretic formulations |
| ES2415357T3 (es) | 2009-06-19 | 2013-07-25 | Krka Tovarna Zdravil, D.D., Novo Mesto | Procedimiento para la preparación de telmisartán |
| WO2011002423A2 (en) * | 2009-07-02 | 2011-01-06 | Mahmut Bilgic | Solubility enhancing pharmaceutical composition |
| WO2011002425A2 (en) * | 2009-07-02 | 2011-01-06 | Bilgig Mahmut | Pharmaceutical composition increasing solubility and stability |
| TR200906506A2 (tr) | 2009-08-24 | 2011-03-21 | Bi̇lgi̇ç Mahmut | Telmisartan içeren katı dozaj formları. |
| WO2011161123A2 (en) | 2010-06-21 | 2011-12-29 | Krka, Tovarna Zdravil, D.D., Novo Mesto | Multilayer pharmaceutical tablet comprising telmisartan and a diuretic |
| EP2952196A4 (en) * | 2013-01-31 | 2016-08-03 | Sawai Seiyaku Kk | MULTILAYER TABLET WITH TELMISARTAN AND HYDROCHLOROTHIAZIDE |
| WO2015012205A1 (ja) * | 2013-07-23 | 2015-01-29 | 第一三共株式会社 | 高血圧症の予防又は治療のための医薬 |
| CN106562973A (zh) * | 2016-11-06 | 2017-04-19 | 成都先先先生物科技有限公司 | 一种抗高血压药物复方制剂 |
| CN107501192A (zh) * | 2017-08-15 | 2017-12-22 | 中国科学院上海药物研究所 | 替米沙坦与氢氯噻嗪的共晶 |
| CN108653227A (zh) * | 2018-08-09 | 2018-10-16 | 湖北舒邦药业有限公司 | 一种替米沙坦氢氯噻嗪片及其制备方法 |
| EP4029867A1 (en) * | 2021-01-13 | 2022-07-20 | Alpha Cognition Inc. | Solid forms of galantamine benzoate gluconate |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE4229085C2 (de) * | 1992-09-01 | 1996-07-11 | Boehringer Mannheim Gmbh | Längliche, teilbare Tablette |
| EA012329B1 (ru) * | 2002-01-16 | 2009-08-28 | Бёрингер Ингельхайм Фарма Гмбх Унд Ко. Кг | Способ получения практически аморфного телмисартана |
-
2005
- 2005-12-09 EP EP05814002A patent/EP1827424A1/en not_active Withdrawn
- 2005-12-09 CA CA002589493A patent/CA2589493A1/en not_active Abandoned
- 2005-12-09 WO PCT/EP2005/013224 patent/WO2006063737A1/en not_active Ceased
- 2005-12-09 AU AU2005315855A patent/AU2005315855A1/en not_active Abandoned
- 2005-12-09 KR KR1020077016354A patent/KR20070097511A/ko not_active Withdrawn
- 2005-12-09 CN CNA2005800434334A patent/CN101080225A/zh active Pending
- 2005-12-09 BR BRPI0519656-6A patent/BRPI0519656A2/pt not_active Application Discontinuation
- 2005-12-09 JP JP2007545905A patent/JP2008524136A/ja active Pending
- 2005-12-09 EA EA200701159A patent/EA200701159A1/ru unknown
- 2005-12-15 PE PE2005001465A patent/PE20060768A1/es not_active Application Discontinuation
- 2005-12-16 TW TW094144909A patent/TW200637546A/zh unknown
- 2005-12-16 AR ARP050105303A patent/AR052052A1/es unknown
- 2005-12-20 UY UY29274A patent/UY29274A1/es not_active Application Discontinuation
-
2007
- 2007-05-04 NO NO20072325A patent/NO20072325L/no not_active Application Discontinuation
- 2007-06-14 IL IL183944A patent/IL183944A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA2589493A1 (en) | 2006-06-22 |
| JP2008524136A (ja) | 2008-07-10 |
| NO20072325L (no) | 2007-07-06 |
| IL183944A0 (en) | 2007-10-31 |
| EA200701159A1 (ru) | 2007-12-28 |
| TW200637546A (en) | 2006-11-01 |
| CN101080225A (zh) | 2007-11-28 |
| UY29274A1 (es) | 2006-07-31 |
| AU2005315855A1 (en) | 2006-06-22 |
| BRPI0519656A2 (pt) | 2009-03-03 |
| KR20070097511A (ko) | 2007-10-04 |
| EP1827424A1 (en) | 2007-09-05 |
| PE20060768A1 (es) | 2006-09-29 |
| WO2006063737A1 (en) | 2006-06-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR052052A1 (es) | Terapia de combinacion | |
| MX2010006283A (es) | Dispositivo implantable de liberacion de farmacos y metodos para tratar la vejiga y otras vesiculas o lumenes corporales. | |
| AR068185A1 (es) | Composiciones de tabletas de desintegracion oral de lamotrigina | |
| EA200870325A1 (ru) | Лекарственные формы для введения комбинаций лекарственных средств | |
| CL2008003595A1 (es) | Compuestos heterociclicos nitrogenados, antagonistas del receptor de taquiquinina; agente farmaceutico que comprende el compuesto; y uso en la profilaxis o el tratamiento de una enfermedad del tracto urinario inferior, una enfermedad gastrointestinal o una enfermedad del sistema nervioso central. | |
| TW200631578A (en) | Methods and compositions using immunomodulatory compounds for treatment and management of central nervous system injury | |
| MX2009003372A (es) | Formas de dosificacion de pelicula no mucoadhesiva. | |
| PE20040134A1 (es) | Forma de dosificacion de una vez al dia de pramipexol | |
| CO6331425A2 (es) | Composiciones que comprenden n-(3,4-difluoro-2-(2-fluoro-4-yodofenilamino)6-metoxifenil)-1-(2,3-dihidroxiproxipropil)ciclopropan-1-sulfamida | |
| AR062860A1 (es) | Combinaciones terapeuticas 482 | |
| UY27532A1 (es) | Forma de dosificación de liberación controlada dual. | |
| CL2011000798A1 (es) | Uso de etexilato de dabigatran o una sal del mismo para preparar un medicamento util para la prevencion del ictus en pacientes que padecen fibrilacion auricular. | |
| CO6220969A2 (es) | Adminsitracion semanal de inhibidores de peptidasa de dipeptidilo | |
| AR051968A1 (es) | Metodos y composiciones que utilizan inhibidores de jnk para el tratamiento y manejo de la lesion del sistema nervioso central | |
| CL2011000625A1 (es) | Preparación sólida que comprende 2-etoxi-1-((2'-(5-oxo-4,5-dihidro-1,2,4-oxadiazol-3-il)bifenil-4-il)metil)-1h-bencimidazol-7-carboxilato de (5-metil-2-oxo-1,3-dioxol-4-il)metilo, un agente regulador de ph y un compuesto antagonista de calcio; y metodos para utilizar y mejorar disolucion del compuesto en la preparacion solida. | |
| AR034517A1 (es) | Formulacion farmaceutica | |
| CL2007002875A1 (es) | Composicion farmaceutica recubierta por una pelicula que comprende capecitabina y al menos un disgregante, util en el tratamiento del cancer para pacientes que tienen dificultad para tragar las formas de dosificacion solidas orales. | |
| AR065139A1 (es) | Medicamento para el tratamiento de la endometriosis | |
| AR048370A1 (es) | Composicion para mejorar funciones cognitivas y la memoria | |
| AR061233A1 (es) | Formulacion de liberacion prolongada de naltrexona | |
| UY26422A1 (es) | Método para administrar un inhibidor de fosfodiesterasa 4 | |
| AR034975A1 (es) | Metodo para el tratamiento del insomnio primario | |
| AR038858A1 (es) | Combinacion | |
| CL2008003558A1 (es) | Composicion farmaceutica que comprende valrubicina y sulfoxido de dimetilo en forma de dosis intravesical, util para tratar cancer a la vejiga. | |
| AR075866A1 (es) | Una dosis de ave5026 para el tratamiento de tromboembolismo venoso en pacientes con deterioro renal severo. uso. composicion farmaceutica. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |